Ultragenyx Pharmaceutical Inc. - RARE
Insiders (Form 4) · last 180 days · showing up to 200 transactions
· Form 144 is shown in the SEC filings tab
· Updating…
Visible: 0
Transaction codes:
P = Open-market purchase ·
S = Open-market sale ·
A = Grant/award ·
M = Exercise/conversion of derivative ·
G = Gift ·
F = Tax withholding ·
J = Other ·
A/D:
A = Acquired (buy/receive) ·
D = Disposed (sell/give)
| Filed | Owner | Title | Code | A/D | Shares | Price | Value | Shares after | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Chief Financial Officer | S | D | 7,066.0 | 15.27 | 107,897.82 | 89,229.0 | View | |
| Sep 15, 2026 | SVP, Chief Accounting Officer | S | D | 1,283.0 | 13.57 | 17,410.31 | 67,863.0 | View | |
| Sep 08, 2026 | SVP, Chief Accounting Officer | S | D | 161.0 | 13.99 | 2,252.39 | 69,146.0 | View | |
| Aug 04, 2026 | EVP and Chief Legal Officer | S | D | 1,900.0 | 24.92 | 47,348.0 | 92,562.0 | View | |
| Aug 04, 2026 | Chief Financial Officer | S | D | 4,696.0 | 24.92 | 117,024.32 | 96,295.0 | View | |
| Jul 06, 2026 | Chief Financial Officer | S | D | 4,698.0 | 33.13 | 155,644.74 | 100,991.0 | View | |
| Jun 15, 2026 | — | S | D | 2,000.0 | 25.05 | 50,100.0 | 21,095.0 | View | |
| Jun 15, 2026 | EVP and Chief Legal Officer | S | D | 1,899.0 | 24.62 | 46,753.38 | 94,462.0 | View | |
| Jun 01, 2026 | Chief Financial Officer | S | D | 4,653.0 | 23.77 | 110,601.81 | 105,689.0 | View |